Gene fusions are vital biomarkers for tumor diagnosis and drug development, with precise detection becoming increasingly ...

We all have a unique face, fingerprint, voice and signature, so why wouldn’t we have a unique response to the medicine and ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated by Repotrectinib, Taletrectinib, and NVL-520 by 2034.

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Blood cancer cases are rising alarmingly among young Indians, with leukemia incidences increasing and bone marrow transplants ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

About two years ago, Katie Bruckmann joined the Covid club when she became infected with the virus for the very first time.

“Larotrectinib continues to demonstrate rapid and durable responses, extended survival, and offers a favorable safety profile in patients with TRK fusion differentiated thyroid cancer, with ...

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer. These findings suggest ...